Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force

J Prev Alzheimers Dis. 2019;6(3):164-168. doi: 10.14283/jpad.2019.12.


Combination therapy is expected to play an important role for the treatment of Alzheimer's disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer's Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and logistical challenges to the development of combination therapy for AD and current efforts to address these challenges. Task Force members unanimously agreed that successful treatment of AD will likely require combination therapy approaches that target multiple mechanisms and pathways. They further agreed on the need for global collaboration and sharing of data and resources to accelerate development of such approaches.

Keywords: Alzheimer’s disease; amyloid; tau; therapeutics; trial design.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Advisory Committees
  • Alzheimer Disease / drug therapy*
  • Animals
  • Clinical Trials as Topic
  • Drug Development*
  • Drug Therapy, Combination
  • Humans
  • Treatment Outcome